Free tool
FAERS Monitor: Bacteriostatic Water For Injection In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018802 or its brand name (Bacteriostatic Water For Injection In Plastic Container, Sterile Water For Injection). Reports on generic versions are filed under their own applications.
Reports
415
Serious
172
41% of reports
Hospitalization
102
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue78
- weight increased43
- weight decreased39
- headache33
- therapy interrupted33
- off label use28
- pain28
- drug ineffective24
- decreased appetite20
- fatigue17
- hospitalisation17
- blood glucose increased16
- inappropriate schedule of product administration16
- injection site pain16
- covid-1915
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 9 |
| 2020 | 55 |
| 2021 | 43 |
| 2022 | 57 |
| 2023 | 58 |
| 2024 | 71 |
| 2025 | 49 |
| 2026 | 64 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,744 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy interruptedSignal | 33 | 23.4 | 16.9 | 688 |
| product dose omission issueSignal | 78 | 13.4 | 11.0 | 899 |
| weight increasedSignal | 43 | 9.7 | 7.3 | 332 |
| weight decreasedSignal | 39 | 7.1 | 5.3 | 200 |
| hospitalisationSignal | 17 | 5.6 | 3.5 | 60 |
| inappropriate schedule of product administrationSignal | 16 | 4.5 | 2.8 | 40 |
| decreased appetiteSignal | 20 | 4.4 | 2.8 | 49 |
| covid-19Signal | 15 | 4.3 | 2.6 | 35 |
| blood glucose increasedSignal | 16 | 4.3 | 2.7 | 38 |
| headacheSignal | 33 | 2.7 | 1.9 | 34 |
| injection site painSignal | 16 | 2.6 | 1.6 | 15 |
| painSignal | 28 | 2.3 | 1.6 | 20 |
| off label use | 28 | 1.6 | 1.1 | 6 |
| fatigue | 17 | 1.1 | 0.7 | 0 |
| drug ineffective | 24 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.